AGT and hypertensive disorder: It is conceivable that instead of blocking multiple GPCRs in certain vascular beds, blockers of EGFR transactivation (e.g. EGFR, MMP inhibitors) could exhibit therapeutic potential by simultaneously inhibiting pathological vasoconstriction and growth in hypertensive disorders, where vasoconstrictive agonists capable of transactivating EGFR, such as catecholamines and angiotensin II, are typically overexpressed and contribute to disease [25,91].